Oncolytics Biotech
Clinical trials sponsored by Oncolytics Biotech, explained in plain language.
Oncolytics Biotech
ONCY
NASDAQ
Develops oncolytic viral immunotherapies for cancer treatment.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Virus-Immunotherapy cocktail takes on tough GI cancers Results expected Jul 2027 (estimated)
- Virus therapy takes on tough colorectal cancer in new trial Results expected Aug 2027 (estimated)